Product logins

Find logins to all Clarivate products below.


Dementia – Epidemiology – Middle East & Africa

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report.

DRG Epidemiology’s dementia forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of dementia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts four dementia patient populations, as follows:

  • Total prevalent cases of dementia.
  • Total prevalent cases of mild dementia.
  • Total prevalent cases of moderate dementia.
  • Total prevalent cases of severe dementia.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Spinal Muscular Atrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness and is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…
Report
Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Several new brands have recently entered the competitive Parkinson’s disease (PD) therapy market, including AbbVie’s Vyalev / Produodopa / Scyova (foslevodopa / foscarbidopa subcutaneous pump…
Report
Myasthenia Gravis – Geography Focus: China – China In-Depth: Myasthenia Gravis
China’s myasthenia gravis (MG) market is transitioning from long-standing symptomatic regimens toward a more structured mix of targeted therapies that increasingly shape treatment pathways…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…